Updated ACOG guidelines strongly recommend systemic hormone therapy with estrogen and a progestogen for women with a uterus, or estrogen alone for those without, to manage vasomotor symptoms and sleep disturbances. This recommendation is based on moderate-quality evidence and applies to women without contraindications, ideally initiated before age 60 or within 10 years of menopause. SSRIs and SNRIs, alongside neurokinin receptor agonists, are recommended for vasomotor and depressive symptoms in patients contraindicated to hormone therapy, supported by moderate- to high-quality evidence. The guidelines replace previous 2014 guidance and reflect a growing consensus among professional societies. Research indicates menopausal hormone therapy is safe and effective for many newly menopausal women. ACOG’s review found that between 50% and 92% of women experience hot flashes or night sweats, and 16% to 66% experience sleep disruptions. Gabapentin, cognitive behavioral therapy, mindfulness-based interventions, exercise, clinical hypnosis, and acupuncture received conditional recommendations for symptom relief. The guidelines consider health inequalities and acknowledge the impact of misinformation, expanding ACOG’s focus on menopause awareness and resources. Studies included data from English-language studies published from 2013 to March 2024, focusing on high-development index countries with an exception for acupuncture studies from China.